At CC Diagnostics, we harness the power of medical advancements to improve the detection of cervical cancer. Our PCR-based reagent kit provide accurate and timely results, ensuring early intervention and better outcomes for patients.
Our cutting-edge technology allows for the early detection of cervical cancer, providing patients with a higher chance of successful treatment. With our innovative approach, we are able to identify abnormalities at the earliest stage, ensuring timely intervention and improved outcomes.
CC Diagnostics
At CC Diagnostics, we believe that early detection is key to improving patient outcomes. Our innovative medical advances are revolutionizing cervical cancer detection, providing accurate and timely results that can save lives.
Cervical cancer is the 4th most common cancer in women that leads to high morbidity and mortality. There is a global inequity in access to screening and treatment.
Each 4-week delay in diagnosis results in a 10% increase in mortality, significantly affecting womens health in a negative and clinically meaningful way.
Current participation of targeted women in cervical cancer screenings is only at 15% due to global inequities and associated emotional and physical barriers.
Current protocol requires multiple samples and works counterproductively. Most currently used screening and triage techniques are not compatible with automation.
Our Solution
Revolutionary screening technology detecting cervical cancer early using novel epigenetic markers.
Currently, cervical cancer screening is inefficient and women-unfriendly. Every year, one million European women receive an incorrect diagnosis, meaning that expensive follow-up tests (such as colposcopy and biopsies)are unnecessarily performed in hospitals. The current test is experienced as unpleasant by women, which is why between 40-59% of the invited women do not participate in the population screening.
Cervical cancer is a disease that can almost always be prevented by adequate screening. However, current screening methods are not sufficiently accurate, which means that every year one million European women are wrongly suspected of having cervical cancer. This leads to a lot of stress, stigmatisation and unnecessary healthcare costs.
The project of CC Diagnostics has received help and funding from the Europees Fonds voor Regionale Ontwikkeling (EFRO) in collaboration with Samenwerkingsverband Noord-Nederland (SNN).
5 out of 5 stars